Press Room

Latest

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001


News - 2017

Uscom ends 2016 with record manufacturing

January 3rd, 2017

Uscom today notified the market that Uscom manufactured record numbers of USCOM 1A devices for the month of December 2016 and for the first half of FY 2017 to meet orders into Chinese, European and US clinical markets. In addition Uscom completed the manufacture of its 1,000th USCOM 1A cardiovascular monitor.

Manufacturing summary

Uscom manufactured a record number of USCOM 1A units for the month of December 2016, and in the second quarter of FY 2017. December quarterly manufacturing represented 42% of the total devices manufactured annually in FY 2016. The number of units manufactured in the first half of FY 2017 increased by 28% on the previous half and Uscom delivered its 1000th USCOM 1A device into global markets.

Uscom is anticipating the sequential commercial release of its new BP+ and BP+ Reporter and SpiroSonic series of devices and the accompanying SpiroReporter software into the Chinese, European and US markets over the next twelve months as regulatory permissions are received. CE approval for the SpiroSonic devices was received last month, with other approvals at various stages of preparation, submission and review. To date all revenue and revenue growth has predominantly been attributable to USCOM 1A sales.

Executive Chairman of Uscom, Associate Professor Rob Phillips said “Uscom is a milestone driven company, and despite complex global dynamics we are continuing our outstanding growth trends into the 5th consecutive year. We are currently preparing for the manufacture and sale of the BP+ and SpiroSonic series of devices into global markets as regulatory approvals are granted. This will involve transitioning to volume manufacturing to meet the current increased demand and the anticipated new demand; a change that will improve supply and margins. It’s really satisfying that our USCOM 1A device is now being adopted world wide in significant numbers to save the lives of children and adults, and remains an innovative cornerstone of advanced haemodynamics – we have effectively changed clinical practice. We anticipate the BP+ and SpiroSonic devices will do the same in complimentary clinical settings and start significantly contributing to revenue over the next 12 months.”

Uscom is the manufacturer of the USCOM 1A, the Uscom BP+, and Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are sold into global medical markets, changing the way clinician diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The products are integral for optimising management of sepsis, guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, for advanced monitoring of hypertension and pre-eclampsia, and in clinical and home care asthma and COPD monitoring.